For a study, it was determined that long-term management of moderate-to-severe Atopic dermatitis (AD) was prevalent. Researchers were to report on the safety and effectiveness of dupilumab therapy in persons with moderate-to-severe Atopic dermatitis for up to three years. The ongoing multicenter, open-label extension study (LIBERTY AD OLE; NCT01949311) evaluated dupilumab therapy in people who had previously participated in dupilumab studies. Dupilumab 300 mg was administered weekly to patients for a total of 148 weeks. The main goal was to keep everyone safe.
About 347 participants reached week 148 out of a total of 2677 patients recruited and treated. The average level of self-reported drug compliance was 98.2%. The safety statistics were consistent with previously published studies (270.1 AEs/100 patient-years; 6.9 severe AEs/100 patient-years) and the established dupilumab safety profile. Nasopharyngitis, Atopic dermatitis, upper respiratory tract infection, conjunctivitis, headache, oral herpes, and injection-site responses were among the most common adverse events (greater than or equal to 5% of patients). AD signs and symptoms improved with time, with a mean (standard deviation, mean percentage change from parent study baseline) Eczema Area and Severity Index of 1.4 (3.2, -95.4%) and a weekly Pruritus Numerical Rating Scale of 2.2 (1.8,- 65.4%) at week 148.
Researchers found out that the safety and effectiveness findings supported the use of dupilumab as long-term, continuous therapy for persons with moderate-to-severe Atopic dermatitis.